Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: back to the future?

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

(2011) Javier Cortes et al.   LANCET

A Phase II Trial of Vinflunine As Monotherapy or in Combination with Trastuzumab as First-Line Treatment of Metastatic Breast Cancer

(2010) Denise A. Yardley et al.   CANCER INVESTIGATION

Phase III Trials of Eribulin Mesylate (E7389) in Extensively Pretreated Patients With Locally Recurrent or Metastatic Breast Cancer

(2010) Chris Twelves et al.   Clinical Breast Cancer

Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine

(2010) Javier Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparison of Studies on Mobile Phone Use and Risk of Tumors

(2010) Florence Samkange-Zeeb et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase III Trial of Ixabepilone Plus Capecitabine Versus Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

(2010) Joseph A. Sparano et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial

(2009) Stacy Moulder et al.   BREAST CANCER RESEARCH AND TREATMENT

nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial

(2009) George Dranitsaris et al.   BREAST CANCER RESEARCH AND TREATMENT

Reply to I.F. Tannock

(2009) Kevin M. Koch et al.   JOURNAL OF CLINICAL ONCOLOGY

Significantly Longer Progression-Free Survival Withnab-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer

(2009) William J. Gradishar et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

(2009) Linda T. Vahdat et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy

(2008) V. Dieras et al.   ANNALS OF ONCOLOGY

Phase I/II Study of Ixabepilone plus Capecitabine in Anthracycline–Pretreated/Resistant and Taxane-Resistant Metastatic Breast Cancer

(2008) Craig Bunnell et al.   Clinical Breast Cancer

Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer

(2008) George Dranitsaris et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE